Koji Izutsu
Director, Department of Hematology
National Cancer Center Hospital · Tokyo, Japan
Leads hematology at Japan's National Cancer Center. Key contributor to Japanese MCL treatment guidelines and clinical trials.
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
International journal of clinical oncology · Nov 1, 2025
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
International journal of clinical oncology · Feb 1, 2024
Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
International journal of hematology · Feb 1, 2024